Search results
Author(s):
Abelardo Martinez
,
Sandy Green
,
James L Januzzi
Added:
3 years ago
Previously considered to be separate disease entities, the acute coronary syndromes (ACS) are somewhat arbitrarily divided on the basis of their electrocardiographic manifestations and are now thought to arise from a common disease process. Based on a number of factors, the severity of the ACS and, consequently, their attendant clinical risk may vary. The management of patients with ACS should…
View more
Author(s):
Alejandro Recio-Mayoral
Added:
1 year ago
Author(s):
Sasha Koul
,
David Erlinge
Added:
3 years ago
Acute coronary syndromes (ACS) are a major reason for death and morbidity in the industrialised world. One of the most successful treatments for ACS has been strategies to target the platelets and inhibit their function.
Mechanisms of Platelet Activation
Thrombus formation in the arteries is dependent on platelets and their ability to attach to the injured wall despite the rapid arterial blood…
View more
Author(s):
Kerry Layne
,
Albert Ferro
Added:
3 years ago
Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation. Antiplatelet therapy has formed the backbone of ACS management for decades and the drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. The main risk…
View more
Author(s):
L Nelson Hopkins
Added:
3 years ago
At least 795,000 people suffer a new or recurrent stroke each year in the US.1 Every 40 seconds, someone in the US has a stroke, and stroke is the third leading cause of death in the US.1 These numbers are likely to increase as the US population ages and as stroke awareness increases. In the past, ischaemic stroke has been managed with palliation and rehabilitation and with prevention of the…
View more
Author(s):
Ziad A Ali
Added:
1 year ago
BCIS ACI 2023 – Dr Ziad Ali (St Francis Hospital & Heart Center, Roslyn, NY, US) summarises his ACI keynote lecture on intracoronary imaging in acute coronary syndromes. Dr Ali briefly discusses the FLAVOUR trial demonstrated that in patients with with intermediate coronary stenosis, FFR-guided PCI is noninferior to IVUS-guided PCI.
Recorded on-site BCIS ACI 2023, London.
View more
B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes
Author(s):
Torbjørn Omland
Added:
3 years ago
Article
Author(s):
Debasish Banerjee
,
Charlotte Perrett
,
Anita Banerjee
Added:
3 years ago
The development of increasingly sensitive and specific serum cardiac biomarkers has led a revolution in the diagnosis and management of acute coronary syndrome (ACS). However, although the troponins now in use are considered highly sensitive cardiac biomarkers in the general population, the interpretation of troponins in patients with acute kidney injury (AKI), chronic kidney disease (CKD) and…
View more
Author(s):
Diego Ardissino
Added:
5 years ago
Diego Ardissino discusses PHARMCLO -Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes.
Filmed by Radcliffe Cardiology on-site at the ACC 2018 congress in Orlando, US.
View more
Author(s):
Giuseppe Rosano
,
Harriette Van Spall
Added:
6 months ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more